In recent years, a series of prospective clinical trials have suggested that BC with low expression of HER2 might be a distinct subgroup of BC, which is different from BC with HER2 negative and HER2 positive in terms of biological characteristics and prognosis. This evidence concerns the gene ERBB2 and breast cancer.